MGH

Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, January 16, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Senior, Patient, Internal medicine, MGH, Harvard Medical School, Rett syndrome, DSM-IV codes, Neuropsychiatry, Harvard College, Central nervous system, Hospital, Teva Pharmaceuticals, Massachusetts General Hospital, Gene editing, Inc., Pharmaceutical industry

Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Julie Jordan, M.D., as Chief Medical Officer.

Key Points: 
  • Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Julie Jordan, M.D., as Chief Medical Officer.
  • She most recently served as Chief Medical Officer of Homology Medicines, a clinical-stage company advancing gene therapies for the treatment of rare diseases.
  • “A proven leader with deep clinical and regulatory expertise to advance pioneering medicines through development, we are thrilled to welcome Julie to the team,” said Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene.
  • Prior to assuming her role as Chief Medical Officer, Dr. Jordan served as the company’s Senior Vice President, Head of Clinical Development and Operations.

BrainCheck Appoints Aaron Greenstein, MD to Clinical Advisory Board

Retrieved on: 
Monday, January 8, 2024
Report, Dementia, Caregiver, The Wall Street Journal, Research, McLean Hospital, Geriatric psychiatry, Massachusetts General Hospital, Ageing, MD, New York Medical College, CO, Human services, Mass, Mass General Brigham, Harvard Review of Psychiatry, Growth, Patient, MGH, News, Policy, Nursing

AUSTIN, Texas, Jan. 8, 2024 /PRNewswire/ -- BrainCheck, Inc. announced the appointment of Aaron Greenstein, MD, a distinguished, board-certified geriatric psychiatrist specializing in geriatric mental illness and dementia, to its clinical advisory board, enhancing the Company's clinical leadership and expertise. Dr. Greenstein, who has worked for some of the most prestigious academic facilities and influential senior healthcare startups, joins the Company as Clinical Advisor following the recent launch of its next-generation platform and 3-minute screening tool, expanding the first end-to-end solution for cognitive care.

Key Points: 
  • AUSTIN, Texas, Jan. 8, 2024 /PRNewswire/ -- BrainCheck, Inc. announced the appointment of Aaron Greenstein, MD, a distinguished, board-certified geriatric psychiatrist specializing in geriatric mental illness and dementia, to its clinical advisory board, enhancing the Company's clinical leadership and expertise.
  • "Dr. Greenstein's expertise will be invaluable as we continue to innovate and strengthen our offerings to better serve healthcare professionals, patients, and caregivers," said Kim Rodriguez, CEO of BrainCheck.
  • "In previous roles, Dr. Greenstein led objective evaluations of available cognitive assessment and care planning tools, and concluded that BrainCheck has the highest clinical utility and efficacy.
  • His research validates the clinical utility of our technology and we look forward to continuing to incorporate his expert acumen as we evolve our solutions and accelerate nationwide adoption."

CARGO Therapeutics Announces Scientific Advisory Board

Retrieved on: 
Wednesday, December 6, 2023
Associate, Baylor University, Baylor College of Medicine, Hospital, Division, Research, Investment company, Massachusetts General Hospital, MD, Doctor of Philosophy, SAB, SAN, Therapy, Cancer, CD2, Health, Section, Dana–Farber Cancer Institute, University, Hematology, Faculty, MBBS, Royal North Shore Hospital, Patient, Boston, Harvard Medical School, MGH, Medical school, CD22, Nursing

SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.

Key Points: 
  • SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.
  • The SAB will provide strategic counsel and critical expertise as CARGO advances its mission to develop the next generation of transformational CAR T-cell therapies.
  • “The SAB stands out by bringing together several highly accomplished translational investigators each with CAR T-cell experience that bridges both the laboratory and the clinic,” said Robbie Majzner, MD, co-founder of CARGO and Scientific Advisory Board Chair.
  • “They are uniquely suited to advise CARGO on their scientific goals and directions that will lead to better outcomes for patients.”
    Members of the CARGO Scientific Advisory Board are listed below; full bios are available on the CARGO website .

Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder

Retrieved on: 
Monday, November 13, 2023
Vitamin D, ASD, Tonix Pharmaceuticals, Osteoporosis, Woman, Adolescence, Safety, MGH, Calcium, Prevalence, Endocrinology, Bone density, IND, BOX, Spectrum, Division, Oxytocin, MPH, Massachusetts General Hospital, Pediatric endocrinology, Neurology, Autism spectrum, Biology, Hospital, Dietary supplement, Pediatrics

CHATHAM, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the first participant was enrolled in an investigator-initiated Phase 2 study of TNX-1900 (intranasal potentiated oxytocin) for improving bone health in children with autism spectrum disorder (ASD), named the BOX study, at Massachusetts General Hospital (MGH). The aim of this Department of Defense-funded study is to investigate the efficacy and safety of TNX-1900 as a novel therapeutic agent to increase bone density and improve bone structure and strength in children with ASD. Tonix is providing active drug and placebo for the BOX study as part of a drug donation agreement with MGH. MGH is the sponsor of the trial, which is being conducted under an investigator-initiated investigational new drug (IND) application.

Key Points: 
  • Tonix is providing active drug and placebo for the BOX study as part of a drug donation agreement with MGH.
  • MGH is the sponsor of the trial, which is being conducted under an investigator-initiated investigational new drug (IND) application.
  • “Low bone density in ASD is a serious problem,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • A Z-score compares one’s bone density to the average bone density of age and gender matched controls.

Hedonia: Novel Approach Finds Dramatic Improvement in Depression Scores in Robust Clinical Trial

Retrieved on: 
Wednesday, December 13, 2023
Software, Other Health, General Health, Telemedicine, Virtual Medicine, Biometrics, Mental Health, Apps, Applications, Technology, Medical Devices, Health Technology, Clinical Trials, Biotechnology, Health, Patient Health Questionnaire, Motivation, Waze, Depression, Research, MGH, Randomized controlled trial, Hippocampus, Patient, Samuel, Psychiatry, Anxiety, FTP, MADRS, DSM-IV codes, MD, Harvard Medical School, Diagnosis, Massachusetts General Hospital, Doctor of Philosophy, Mental health, Hospital, Pharmaceutical industry, Nursing, Medical device

This is the first study to use a therapeutic app based on Facilitating Thought ProgressionTM (FTP), a novel approach to mood disorders that disrupts cyclical, repetitive patterns of rigid thinking common in depression and anxiety.

Key Points: 
  • This is the first study to use a therapeutic app based on Facilitating Thought ProgressionTM (FTP), a novel approach to mood disorders that disrupts cyclical, repetitive patterns of rigid thinking common in depression and anxiety.
  • All participants continued their ongoing conventional treatment (medication, therapy, or both), if they were already on any, during the study.
  • On the Montgomery-Asberg Depression Rating Scale (MADRS), a clinician-administered assessment, the depression severity scores of participants in the intervention group dropped by 43%, while the control group’s scores dropped by 18%.
  • The researchers emphasized that this is the first study to examine the delivery of FTP using a mobile application.

Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City

Retrieved on: 
Monday, November 20, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Psychopharmacology, Mental, Research, NYSE, MGH, Carlsberg Foundation, DSM-IV codes, Psychiatry, National academy, Dean (education), Endocrinology, Literature, European College of Neuropsychopharmacology, Book, Functional neuroimaging, Rigshospitalet, NEO, National Academy of Medicine, Medicine, University of Copenhagen, Neurology, Neuropharmacology, University, Epilepsy, Harvard Medical School, Human Brain Project, Letter, Society, Inc., Science, Hospital, Royal Danish Academy, Pharmaceutical industry, Depression

Dr. Fava is a world leader in the field of depression and clinical psychopharmacology.

Key Points: 
  • Dr. Fava is a world leader in the field of depression and clinical psychopharmacology.
  • Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology at the same university.
  • He founded and was director of the hospital’s Depression Clinical and Research Program from 1990 until 2014.
  • Professor Knudsen received her medical and doctoral degrees from the University of Copenhagen, Denmark and completed her training in neurology.

Rocket Science Health to Present Data Related to Its In-Development Targeted Intranasal Drug Device at Boston CNS Summit

Retrieved on: 
Wednesday, December 6, 2023
CNS, Field, Brain, Research, Bachelor of Science, MGH, Organization, Science, FDA, University, Harvard Medical School, Death, Massachusetts General Hospital, Disability, North Carolina State University, Doctor of Philosophy, Neurological disorder, Central nervous system, Microsoft, Autism spectrum, Health, Hospital, Transport, Pharmaceutical industry, Nursing, Chemistry, Boston, Radiology

Currently, about 95 per cent of small molecule and nearly all large molecule drug therapies approved by the FDA cannot cross the blood brain barrier.

Key Points: 
  • Currently, about 95 per cent of small molecule and nearly all large molecule drug therapies approved by the FDA cannot cross the blood brain barrier.
  • A breakthrough in delivery of drugs to the brain would be significant for the treatment of many central nervous system (CNS) disorders.
  • Rocket Science Health also announced the appointments of two seasoned experts to support the growing company: Sohier Hall, as President; and Dr. Jacob Hooker, as Chief Science Advisor.
  • Rocket Science Health, founded by business leader Kenneth Irving, is a private, B.C.-based healthcare technology company that is revolutionising direct to brain drug delivery.

Mitsubishi Tanabe Pharma America Announces Presentations in ALS at 34th International Symposium on ALS/MND

Retrieved on: 
Tuesday, December 5, 2023
Data mart, SVC, Research, Safety, ALS, MGH, State university system, Motor Neurone Disease Association, Spirometry, Disease, CET, MTPA, Part, MNDA, Medical Affairs Bureau, Abstract, CDM, Edaravone, Massachusetts General Hospital, NCRI, Hospital, Pharmaceutical industry, Communications satellite, Telehealth, Biomarker, Patient, Optum

JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four abstracts in amyotrophic lateral sclerosis (ALS) will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8.

Key Points: 
  • JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four abstracts in amyotrophic lateral sclerosis (ALS) will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8.
  • MTPA's posters will be displayed during poster sessions held in the Event Halle on December 6 and 7.
  • A Preliminary Analysis of Oral Edaravone-Treated Patients with Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database (Malgorzata Ciepielewska, M.S.
  • ; State University of New York Upstate Medical University)
    Poster Session B (Part 1), 5:45 p.m. – 6:45 p.m. CET, Dec. 7

AI Model Predicts Breast Cancer Risk Without Racial Bias

Retrieved on: 
Wednesday, November 29, 2023
Health, Woman, RSNA, Research, MGH, American Cancer Society, AUC, Risk, Hospital, Breast cancer, Patient, Multimedia, Medicine, DCIS, Ductal carcinoma, Risk assessment, Newsroom, Deep learning, Cancer, Survival, Massachusetts General Hospital, Biomarker, AI, Society, Radiology, Radiation, Education, Medical imaging, Birth control, Medical device, Boston

Traditional breast cancer risk assessment models use information obtained from patient questionnaires, such as medical and reproductive history, to calculate a patient's future risk of developing breast cancer.

Key Points: 
  • Traditional breast cancer risk assessment models use information obtained from patient questionnaires, such as medical and reproductive history, to calculate a patient's future risk of developing breast cancer.
  • According to the American Cancer Society, Black women demonstrate the lowest 5-year relative survival rate for breast cancer among all racial and ethnic groups.
  • A deep learning AI risk assessment model developed using mammographic images alone can outperform traditional risk assessment models in future breast cancer development while also mitigating the racial biases seen in traditional models.
  • The deep learning model consistently outperformed traditional risk models in predicting a woman's risk of developing DCIS, which is early-stage breast cancer, and invasive breast cancer, which is cancer that has potential to spread.

AI Identifies Non-smokers at High Risk for Lung Cancer

Retrieved on: 
Wednesday, November 22, 2023
Deep learning, Medicine, Lung, Health, RSNA, Smoker, Research, MGH, National academy, Incidence, American Cancer Society, National Comprehensive Cancer Network, Risk, Disease, Hospital, Mortality, Serum, B.A, Patient, Respiratory tract infection, Tobacco, Smoke, Artificial intelligence, Knowledge Organization (journal), Non-Smokers' Rights Association, USPSTF, Prostate, Lung cancer screening, Lung cancer, Newsroom, Harvard Medical School, Diagnosis, CIRC, Massachusetts General Hospital, Medicare, Chronic obstructive pulmonary disease, Biomarker, Cancer, Society, Radiology, Radiation, Education, Risk management, Medical imaging, Boston

The American Cancer Society estimates about 238,340 new cases of lung cancer in the United States this year and 127,070 lung cancer deaths.

Key Points: 
  • The American Cancer Society estimates about 238,340 new cases of lung cancer in the United States this year and 127,070 lung cancer deaths.
  • Existing lung cancer risk scores require information that is not readily available for most individuals, such as family history of lung cancer, pulmonary function testing or serum biomarkers.
  • For the study, CIRC researchers set out to improve lung cancer risk prediction in never-smokers by testing whether a deep learning model could identify never-smokers at high risk for lung cancer, based on their chest X-rays from the electronic medical record.
  • The high-risk group well exceeded the 1.3% six-year risk threshold where lung cancer screening CT is recommended by National Comprehensive Cancer Network guidelines.